The Cancer Letter

Inside information on cancer research and drug development

Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays

In Brief

Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor

ARPA-H to award up to $150M to develop novel technologies for precise tumor removal 

UIUC receives $18.7M from ARPA-H to develop platform for rapid manufacturing of tumor models

McKesson to acquire controlling stake in Florida Cancer Specialists & Research Institute’s Core Ventures

Florida Cancer Specialists & Research Institute, Paradigm Health collaborate to expand patient access to clinical trials

Simon Nazarian named chief digital and technology officer at City of Hope

Drugs & Targets

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

EC approves Padcev + Keytruda for advanced urothelial cancer

In The Clinic
Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Trials & Tribulations
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account